Body Mass Index and Clinical Benefit of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer

Obesity is a known risk factor for breast cancer and has been linked to increased risk of recurrence and death in breast cancer patients. Little is known about the predictive value of obesity. As endocrine therapy is widely used for breast cancer treatment worldwide, we aimed at correlating baseline body mass index (BMI) with clinical benefit derived from fulvestrant in postmenopausal women with advanced breast cancer.We analyzed consecutive...